검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Epoetin Alfa |
Overview Company | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Overview Modality | ADC |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | Anemia; Leukemia |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | biomarker for CKD diagnosis, circ_DLGAP4/SOX7 as a novel panel useful for assessing CKD progression using a n |
PK/PD Species | Hamster |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Hamster |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Efficacy, safety, and immunogenicity of UB-851 versus ® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trial.. Anemia is a common complication in patients with chronic kidney disease (CKD), for which recombinant human erythropoietin (rhEPO) is the standard treatment. UB-851 is a biosimilar rhEPO developed as an alternative to epoetin alfa (Eprex &… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 34 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Epoetin Alfa |
Overview Company | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
Overview Modality | ADC |
Overview Target | Acute Myeloid Leukemia |
Overview Indication | Anemia; Leukemia |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | biomarker for CKD diagnosis, circ_DLGAP4/SOX7 as a novel panel useful for assessing CKD progression using a n |
PK/PD Species | Hamster |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Hamster |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Efficacy, safety, and immunogenicity of UB-851 versus ® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trial.. Anemia is a common complication in patients with chronic kidney disease (CKD), for which recombinant human erythropoietin (rhEPO) is the standard treatment. UB-851 is a biosimilar rhEPO developed as an alternative to epoetin alfa (Eprex &… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 34 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교